Physician profile
Julia C Graves
NPI 1780646554
$7,112.52
in general payments reported to CMS, 2019-2025
42 companies · $50.65 in 2025
The $50.65 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,239 · 2020: $968 · 2021: $1,403 · 2022: $1,068 · 2023: $1,690 · 2024: $694 · 2025: $50.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,434.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $914.32 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $716.36 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $608.45 | 2019-2024 | Mounjaro, Trulicity, Emgality |
| Novo Nordisk INC | $564.41 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $438.59 | 2019-2023 | Steglatro, Belsomra, Segluromet |
| Glaxosmithkline, LLC. | $400.40 | 2019-2023 | Shingrix, Arexvy, Bexsero |
| Gilead Sciences, INC. | $363.12 | 2019-2021 | |
| Amgen INC. | $360.94 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $315.86 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.22 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $269.18 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $202.59 | 2020-2024 | Spravato, Xarelto |
| Pfizer INC. | $199.37 | 2019-2024 | |
| Galderma Laboratories, L.P. | $166.17 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.79 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.